Transmission of Immunoproteasomes Via Extracellular Vesicles: Implications for Immune Modulation Research

Study Background and Research Question

The ubiquitin–proteasome system (UPS) is essential for selective protein degradation, antigen processing, and cellular homeostasis. A specialized form, the immunoproteasome (iP), incorporates immune subunits—β1i (LMP2), β2i (MECL-1), and β5i (LMP7)—in response to inflammatory cytokines such as IFN-γ and TNF-α. These iPs are crucial for generating peptides that bind MHC class I molecules, thereby regulating antigen presentation and immune responses. While extracellular vesicles (EVs) have been recognized as carriers of various cellular components, the direct transfer of non-constitutive (including immunoproteasome) complexes between cells had not been established. The central research question addressed by Grigorieva et al. (2026) is whether immunoproteasomes can be packaged into EVs and functionally delivered to recipient cells (paper).

Key Innovation from the Reference Study

This research is the first to experimentally demonstrate that immunoproteasomes are not only secreted in EVs but can also be transferred and detected in recipient cells. By using genetically engineered cell lines expressing a β5i-mCherry fusion protein, the investigators provided direct molecular evidence for the intercellular transmission of immunoproteasome subunits through EVs. This innovation provides a new mechanism by which immune cell function and antigen presentation capacity can be modulated beyond the confines of individual cells (paper).

Methods and Experimental Design Insights

The authors employed a combination of molecular biology, cell engineering, and advanced vesicle isolation techniques. The main experimental system involved human SW620B8-mCherry adenocarcinoma cells stably expressing a β5i-mCherry chimera, allowing for the fluorescent tracking of the immunoproteasome subunit within donor and recipient cells. Extracellular vesicles were isolated via differential centrifugation, affinity isolation, and unspecific precipitation. Nanoparticle tracking analysis (NTA) and fluorescence microscopy characterized the EV populations and confirmed the presence of β5i-mCherry protein.

Recipient cells were incubated with isolated EVs, and subsequent detection of the β5i-mCherry fusion in their lysates indicated successful transfer. The experimental design included stimulation with IFN-γ to upregulate immunoproteasome expression and EV packaging, as well as the use of multiple cell lines to generalize findings across different cellular contexts (paper).

Core Findings and Why They Matter

Major findings include:

• Immunoproteasome Packaging in EVs: Diverse cell lines secrete EVs containing non-constitutive proteasomes, with EV yield and content increasing after IFN-γ stimulation (paper).
• Functional Transfer to Recipient Cells: The β5i-mCherry fusion protein was detected in lysates of recipient cells, indicating direct transfer of immunoproteasome subunits via EVs.
• Potential for Intercellular Immune Modulation: These results suggest that immunoproteasome activity, and thus antigen processing, can be modulated not just by cell-intrinsic expression but also by vesicle-mediated intercellular communication.

This mechanism expands the conceptual framework for understanding immune system regulation. For autoimmune disease models and cytokine production blockade strategies, the possibility that cells can acquire immunoproteasome activity from neighbors via EVs provides a new layer of complexity and may influence therapeutic targeting, especially in tissues with high EV exchange rates.

Comparison with Existing Internal Articles

Several internal resources focus on the role of immunoproteasome inhibition in disease and the use of selective inhibitors such as ONX-0914 (PR-957):

• "ONX-0914 (PR-957): Advanced Immunoproteasome LMP7 Inhibit..." explores how LMP7 inhibition modulates immune pathways in autoimmune disease models, providing mechanistic detail on cytokine regulation and disease attenuation. The reference paper's findings suggest that vesicle-mediated transfer may alter the landscape of inhibitor efficacy if immunoproteasome activity can be replenished intercellularly.
• "Immunoproteasome Inhibition Alters Synaptic Plasticity in Mice" addresses non-immune effects of immunoproteasome inhibition. The demonstration of intercellular transfer in the reference study hints at possible explanations for system-wide outcomes, even in the CNS, where EV-mediated protein transfer is increasingly recognized.
• Articles such as "ONX-0914: Selective Immunoproteasome Inhibitor for Autoim..." emphasize the precision of ONX-0914 in modulating cytokine profiles, supporting the idea that targeting EV-associated immunoproteasome transmission may be a future area of preclinical research.

Limitations and Transferability

While the study delivers novel mechanistic insights, several limitations should be noted:

• Cell Model Specificity: Experiments were performed in cancer-derived and immortalized cell lines; primary immune cell validation and in vivo confirmation are necessary for full translational relevance.
• Functional Consequences: The study confirms transfer of immunoproteasome subunits but did not directly address whether recipient cell function (e.g., antigen processing or cytokine production) was altered as a result.
• Quantitative Aspects: The extent to which EV-mediated transfer contributes to total cellular immunoproteasome activity in tissue contexts remains to be determined.

Nevertheless, the transferability of the findings is high for researchers studying immunoproteasome inhibition in autoimmune disease, as EV-mediated replenishment may influence the robustness and duration of pharmacological blockade strategies.

Protocol Parameters

• EV isolation (differential centrifugation) | 100,000 × g, 70 min | suitable for small EVs | standard in EV research, enables recovery of microvesicles/exosomes | paper
• IFN-γ stimulation | 100–500 IU/mL, 24–48 h | upregulates immunoproteasome expression | mimics inflammatory cytokine milieu | paper
• ONX-0914 (PR-957) concentration for LMP7 blockade | 10–100 nM (in vitro PBMCs) | cytokine inhibition assays | achieves >90% IL-23, ~50% TNF-α/IL-6 inhibition | product_spec
• ONX-0914 solubility | ≥29.03 mg/mL in DMSO, ≥69 mg/mL in ethanol | stock solution preparation | maximizes compound availability for in vitro assays | product_spec

Research Support Resources

For researchers aiming to dissect the role of immunoproteasome transmission or to block iP activity in disease models, ONX-0914 (PR-957) (SKU A4011) is a selective LMP7 inhibitor widely used in cytokine production blockade and arthritis research (internal article). Detailed handling and protocol guidance is available from APExBIO and published workflows. This tool compound can help clarify the interplay between endogenous and EV-mediated immunoproteasome function in both in vitro and in vivo systems.